Back to Stakeholders
Journey Colab is a US psychedelic pharmaceutical company developing synthetic mescaline hydrochloride for alcohol use disorder (AUD). Founded in 2020, the company has raised $30.7M from investors including Sam Altman, Apollo Projects, and Drew Houston. Journey Colab has dedicated 10% of its founding equity to a Reciprocity Trust supporting Indigenous communities from which mescaline knowledge originates. The company is partnering with All Points North (APN) for an FDA-authorised Phase 2 clinical trial.
Drug Pipeline
1Synthetic mescaline HCl
MescalinePhase I/II
Moving toward FDA IND filing for a Phase 2 trial of mescaline-assisted therapy for AUD; partnership with All Points North in a real-world treatment setting.
Quick Facts
- Type
- Private Biotech
- Founded
- 2020
- Lead Stage
- Phase I/II
- Website
- Visit